Skip to main content

Harry Hixson, Mats-Olof Wallin, George Rathmann, Ted Love, Richard Brewer, Mary Pendergast, Phillipe Chambon, Jean-Francois Formela, Martin Vogelbaum

Premium

Sequenom recruited former Amgen CEO Harry Hixson to its board, the company said Jan. 14. Hixson is currently chairman and CEO of privately held drug firm Elitra Pharmaceuticals.


Pyrosequencing named Mats-Olof Wallin CFO, capping a broad restructuring begun in October.

Wallin, 51, is currently CFO of Ortivus, a Swedish medical technology company. He will oversee Pyrosequencing’s financings in Sweden and in the US.


Hyseq and Variagenics have named six board members and a chairman to oversee the new — and still unnamed — company set to emerge Jan. 28 [see accompanying story, page 3]. From the Hyseq side, Chairman George Rathmann, 75, will retain his title at the new firm. He will be joined on the board by Hyseq compatriots Ted Love, 43; Richard Brewer, 51; and Mary Pendergast, 52. Variagenics, meantime, will chip in Phillipe Chambon, 44; Jean-Francois Formela, 46; and Martin Vogelbaum, 39.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.